Respiratory Syncytial Virus
Pipeline by Development Stage
Drug Modality Breakdown
Respiratory is a $39.4B mature market dominated by established inhalers and combination therapies with significant patent cliff risk.
Key Trends
- Consolidation around GSK's triple-therapy franchises (Trelegy, Breo, Anoro)
- Major patent expirations 2026-2031 creating $7.8B revenue cliff
- High clinical trial activity (4,862 trials) suggesting pipeline innovation despite market maturity
Career Verdict
Respiratory offers stable commercial careers but limited growth upside; best for professionals seeking established markets with strong commercial infrastructure rather than innovation-driven advancement.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 46% | Launch | Growing | 15.0yr |
| 2 | TRULICITY (dulaglutide) | Eli Lilly and Company | $7.4B | 19% | Peak | Stable | |
| 3 | TRELEGY ELLIPTA (fluticasone/umeclidinium/vilanterol) | GSK | $4.5B | 11% | Peak | Declining | 4.9yr |
| 4 | CREON (pancrelipase) | AbbVie | $1.5B | 4% | Approaching LOE | Declining | |
| 5 | BREO ELLIPTA (fluticasone/vilanterol) | GSK | $1.4B | 4% | Peak | Declining | 4.9yr |
Drug Class Breakdown
dominant market driver
fragmented portfolio
rapidly expanding
legacy product
patent cliff approaching
mature maintenance therapy
Career Outlook
StableRespiratory is a stable, mature market suitable for commercial and medical affairs professionals seeking established career paths, but offers limited growth or innovation-focused opportunities. The impending patent cliff ($7.8B+ revenue at risk 2026-2031) will drive near-term restructuring and consolidation, potentially reducing headcount in 2027-2028. Professionals should expect strong compensation in Medical Affairs and field roles but limited advancement into strategic or R&D positions.
Breaking In
New graduates should prioritize commercial, field-based, or Medical Affairs roles over R&D; respiratory offers structured training and stable compensation but limited innovation exposure, so pair this experience with cross-therapeutic skill-building for long-term mobility.
For Experienced Professionals
Experienced professionals should evaluate whether to maximize earnings in this mature, stable market or transition to higher-growth areas (oncology, cell therapy); respiratory consolidation 2027-2030 will reduce senior-level opportunities, so consider strategic moves before patent cliff impacts headcount.
In-Demand Skills
Best For
Hiring Landscape
The respiratory sector shows modest hiring momentum (510 jobs across tracked positions) concentrated in commercial and engineering roles, with AstraZeneca and GSK leading. Medical Affairs positions command premium salaries ($314K avg) but represent only 3% of openings, reflecting the mature market's focus on sales execution over innovation. Hiring velocity is moderate and reflects market consolidation rather than expansion, suggesting limited career progression opportunities for early-to-mid career professionals.
Top Hiring Companies
By Department
Respiratory hiring favors commercial and field-based roles over R&D; Medical Affairs roles offer premium compensation but are scarce, making this area competitive for specialized talent.
Competitive Landscape
13 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 20 trials with date data
Clinical Trials (20)
Total enrollment: 69,932 patients across 20 trials
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea
A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age
Phase II Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 50 Years or Above
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus
Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)
A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
Phase I Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 18 Years or Above
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive
Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults
Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy
BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)
Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study
A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of Age
Comparison of Nylon Flocked Swabs and Saline Aspirates for Detection Respiratory Viruses
Related Jobs in Respiratory
Head of Medical Affairs & GCSP (Global Clinical Safety & Pharmacovigilance)
(Bio-)Chemiker Analytik, M.Sc. (w/m/d)
Compliance Director
Medical Device Sales Associate Territory Account Manager
Sr. HR Operations Specialist
Medical Device Sales Territory Account Manager
Phase Legend
Key Insights
Related Indications
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.